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1  | OVERVIE W
1.1 | Statement from the 2019- 20 BAHNO 
President
The Association was first constituted in 1967 as the Association of Head 
and Neck Oncologists of Great Britain and in 1995 changed its name to 
the British Association of Head and Neck Oncologists (BAHNO). The 
stimulus for its formation remains our aim, namely the need to encour-
age discussion and the sharing of knowledge between the various clini-
cal and research specialties involved in the management of the diverse 
group of conditions that make up head and neck cancer. Although those 
of us working in the field have strong links with other relevant individ-
ual medical and paramedical specialties BAHNO remains the only truly 
multidisciplinary professional group which can represent the interests 
of head and neck cancer clinicians and patients in the United Kingdom.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2021 The Authors. Journal of Oral Pathology & Medicine published by John Wiley & Sons Ltd.
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BAHNO first published a document on the provision and 
quality assurance for head and neck cancer as long ago as 2002, 
setting standards for multidisciplinary care in so doing. In 2009, 
it once again contributed to the continuing improvements in the 
management of our patients by publishing standards for the pro-
cess of head and neck cancer care that have been used both within 
the United Kingdom and abroad as a vehicle for change over the 
past decade. I am delighted that BAHNO has once again been at 
the forefront of clinical improvement in publishing this document 
which continues the theme of the association in representing the 
multidisciplinary nature of our work in treating head and neck 
cancer.
I would like to thank the contributors for their tireless work and 
in particular Stuart C Winter and Andrew Schache for overseeing the 
project and bringing this publication to the light of day.
Professor Cyrus Kerawala
BAHNO President
2  | TERMS OF REFERENCE
This standards document represents the revised and updated 
BAHNO Standards previously published in 2009.
These Standards pertain primarily, although not exclusively, to 
the configuration and organisation of services tasked with the man-
agement of individuals with squamous cell carcinoma of the head 
and neck. Within this context, salivary and regional metastases of 
cutaneous squamous cell carcinoma of the head and neck are also 
considered. The standards have taken reference from national pub-
lished guidance to inform the recommendations.1- 15
The 2020 BAHNO Standards have been updated to include thy-
roid malignancies in keeping with the role that members of special-
ities aligned to BAHNO play in the overwhelming majority of these 
cancers.
Whilst there are elements of these Standards that might sim-
ilarly be applicable to units/trusts providing management of sar-
comas and/or lymphoproliferative diseases, these tumour types 
were not specifically considered within the remit of these BAHNO 
Standards.
3  | SERVICE CONFIGUR ATION
3.1 | Co- ordination of services
ALL units/centres should have a named head and neck clinical lead 
responsible for the overall unit.
ALL units should have a named lead responsible for co- ordinating 
the local provision of care.
ALL individuals should be seen by a specialist head and neck 
nurse/clinical nurse specialist (eg Macmillan nurses in the UK) whose 
contact details should be made available to the patient at the earliest 
opportunity.
ALL centres should have a list of consultants who are designated 
to provide head and neck cancer care.
3.2 | Referral to specialist head and neck 
cancer services
Referrals should adhere to national and local guidelines. Referrals 
using the UK “Two- week wait (2WW)” pathway should have suf-
ficient detail to allow for triage into the most appropriate clinic. 
Referrals should contain sufficiently detailed information such that 
pre- referral investigations can be completed if necessary. There 
should be a secure image transfer system so any accessible lesions 
(inc. oral cavity) can be assessed. There should be an agreed path-
way for a senior clinician to downgrade 2WW referrals if considered 
benign.
Referral outside the urgent pathway, particularly by routine mail, 
should be discouraged. However, where unavoidable, the same in-
formation is required.
The referral system should be sufficiently robust to support re-
ferral from both general medical and dental practitioners.
Referrals should be sent to appropriate specialties:
• Hoarseness to ear, nose and throat surgery (ENT)
• Oral ulcers/lesions to oral and maxillofacial surgery (OMFS)
• Neck lumps/salivary gland lesions to ENT or OMFS
• Suspected unknown primary of the head and neck to ENT or 
OMFS
• Management of neck and parotid lumps in those individuals 
under the care of other specialties (eg skin cancer patients 
treated by plastic surgeons, ENT or OMFS) will reasonably 
continue to ensure continuity of care, ensuring appropriate 
head and neck MDT discussion still occurs. Onward referral 
to dedicated head and neck services should be made where 
appropriate.
No patients presenting with the above conditions should be re-
ferred to general surgeons.
There should be an awareness and consideration of the national 
guidance regarding the urgent cancer diagnostic services.
3.3 | Information technology
ALL host trusts should provide funding for hardware, software, an-
nual licenses and updates to maintain the services detailed in these 
Standards.
ALL trusts should also provide adequate administrative support 
to collect and enter data into regional and national cancer registries.
ALL units to have a named and dedicated IT co- ordinator.
ALL trusts should have strategic plans to introduce IT and path-
way solutions capable of continually optimising head and neck can-
cer pathways (diagnostic and therapeutic).
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3.4 | Patient information
3.4.1 | Documentation of information provided to 
individuals and carers following a “significant (bad) 
news” consultation
All individuals should be made aware of their diagnosis unless they 
make an express wish to the contrary. The subsequent depth of de-
tail provided should be tailored to the individual’s requests but must 
be sufficient to allow the making of informed decisions.
All patient notes should document what the individual and his/
her carers have been told about the diagnosis, the aims of treatment 
and the treatment being offered.
3.4.2 | Communication with primary care
Serious diagnosis communication should be made with primary care 
physicians in ALL instances following a new diagnosis of cancer.
Following admission for definitive surgery or completion of can-
cer treatment, units should have a written protocol and or/checklist 
including:
• Brief overview of the treatment received
• Name and contact details of head and neck key worker for individ-
uals/carers and GP
• Diagnosis, treatment undertaken and complications with dates
• Follow- up arrangements.
3.4.3 | Information about treatment
Patients should be provided with consistent information and sup-
port at diagnosis in line with the NICE service guidance on improv-
ing outcomes in head and neck cancer and recommendations of the 
National Peer Review Programme. Where appropriate, this should 
include details of disease aetiology (eg information about Human 
papillomavirus (HPV) to individuals with HPV- associated oropharyn-
geal squamous cell carcinoma).
Information and support should be tailored to the individual’s 
needs (including the benefits and side effects of treatment, psycho-
social and long- term functional issues).
Details of available peer- support services should be made available 
to patients for all standard treatment pathways— this may be in vari-
able formats (eg written leaflets, brail and electronic) and languages.
4  | DIAGNOSIS AND STAGING
4.1 | Outpatient facilities
ALL units to have appropriate equipment such that clinical images 
can be taken and used and shared for disease monitoring and MDT 
discussion.
It is desirable to have access to narrow band imaging.
ALL outpatients should have video screens to sup-
port provision of nasendoscopy and rigid endoscopy of the nasal 
cavity.
There should be facilities for photo- documentation with digital 
storage.
The following should be available in the head and neck outpa-
tient setting:
• A microscope available for aural examinations
• Facilities for dental assessments, minor oral surgery (biopsy and 
dental extractions) and dental radiology, the latter to include the 
minimum of a dental panoramic tomogram (DPT) but where pos-
sible to include access to intra- oral radiographs
• Appropriate personal protective equipment (PPE) available as rec-
ommended by national guidelines.
4.2 | Examination under anaesthesia
There should be facility for ALL individuals to undergo examination 
under anaesthesia (EUA) where the clinician deems it necessary to 
make robust therapeutic decisions.
4.3 | Radiology
Standard imaging protocols should be applied for ALL CT, 
MRI, ultrasound and FDG PET- CT studies, and these should 
comply with Royal College of Radiologists’ recommendations or 
equivalent.
Cross- sectional imaging CT/MRI should be reported by a special-
ist head and neck radiologist. ALL head and neck imaging should be 
reported by this dedicated team.
PET/CT should be reported by specialist head and neck nuclear 
medicine physician/radiologist.
All staging scans should be reported prior to commencement of 
treatment and, ideally, prior to primary tumour biopsy.
Systemic imaging (thoracic CT) should be available for ALL 
individuals with cancer of the upper aerodigestive tract. In 
early- stage disease (eg T1N0 or T2N0), this should not delay 
treatment.
ALL sites must have access to CT/MRI for imaging of ALL individ-
uals, to conform with RCR guidance.
PET- CT should be available for the assessment of:
• An unknown primary
• T4 cancer of the hypopharynx or nasopharynx
• N3 staging of cancer of the upper aerodigestive tract
• Tumour response after treatment with chemoradiotherapy.
A DPT is required as a minimum for all patients prior to under-
going a dental assessment. This assessment should be supported by 
intra- oral radiographs where necessary.
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4.4 | Pathology
4.4.1 | Fine- needle aspiration
Provide fine- needle aspiration cytology/core biopsy analysis for ALL 
individuals with a neck lump that is suspected of being cancer of the 
upper aerodigestive tract. This should be performed by a specialist 
radiologist, pathologist or clinician. The biopsy laterality and biopsy 
site must be documented in ALL instances.
Aim to perform ALL fine- needle aspiration cytology or core sam-
pling under ultrasound guidance. ALL ultrasound- guided fine- needle 
aspiration cytology should be subject to rapid on- site evolution/as-
sessment (ROSE/ROSA).
Fine- needle aspiration or biopsies should be interpreted by a 
cytopathologist with head and neck interest and reported within 7 
calendar days.
4.4.2 | External pathology
In ALL units, capacity should be available to review biopsy speci-
mens of cancer diagnosed in primary or secondary care. Where this 
deemed necessary, it should be by a specialist head and neck pa-
thologist within the tertiary care setting.
4.4.3 | Pathology in the MDT
ALL new cases should have a histological diagnosis of cancer prior to 
treatment planning (except in exceptional circumstances, eg in individ-
uals for whom an open or core biopsy is inappropriate or not possible).
Surgical margins must be discussed for ALL patients within the 
MDT and documentation made of the significance and recommen-
dation for acting on close or involved margins.
4.4.4 | Reporting
ALL surgically resected cases should include all core data set items 
for head and neck cancer histopathology reporting. There should be 
at least one named pathologist per centre participating in the na-
tional external quality assurance scheme.
ALL incisional biopsies and core biopsies for suspected cancer 
should be reported within 7 calendar days (confirming or excluding 
diagnosis of malignancy as a minimum).
Reporting of definitive resection specimens should be reported 
within 10 calendar days where decalcification is not required.
ALL squamous cell carcinomas of the oropharynx should be 
tested to determine HPV status.
ALL centres should have access to:
• Diagnostic and predictive molecular testing
• Histological frozen section facilities for intra- operative diagnosis 
where units offer surgical treatment.
4.5 | Multidisciplinary head and neck cancer clinics
4.5.1 | Timetabling
ALL individuals should be staged weekly in each unit undertaking 
head and neck cancer treatment using the current staging (TNM8 at 
time of publication).
The structure of the multidisciplinary team (MDT) must allow 
capability for membership of the MDT to participate virtually (eg 
teleconference/video conference).
4.5.2 | Staffing
It is recommended that, as a minimum, the MDT should consist of 
the following professionals with specialist interest in head and neck 
cancer:
• At least four appropriately trained Head and Neck surgeons (at 
least 50% of time devoted to head and neck oncology), at least 
one of whom should have specialist head and neck reconstructive 
skills
• There should be both a surgeon and an oncologist at all MDT 
clinics
• At least two head and neck oncologists (at least 50% of time de-
voted to head and neck oncology) present in 100% of clinics
• Clinical nurse specialist*
• Speech and language therapist*
• Dietitian*
• Histopathologist and cytopathologist
• Radiologist
• Restorative dentist
*The number needs to be sufficient to cover the MDT at all times, 
for example leave and absence.
There should be a pathway for ALL units to refer for additional 
support services including (but not exclusively):
• Psychological support
• Lymphoedema care
• Financial welfare support
• Physiotherapy and occupational therapy.
ALL individuals with palliative care needs (anticipated or other-
wise) should have both timely referral and clear access to their local 
palliative care services.
4.5.3 | MDT clinic configuration
Facility should be available for both a head and neck surgeon and 
a head and neck oncologist to undertake joint consultations (par-
ticularly where treatment equipoise exists or where support of com-
bined treatment planning is necessary).
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4.6 | Multidisciplinary team meetings
4.6.1 | Individual patient discussion
ALL individuals with a new or recurrent head and neck cancer diag-
nosis should be discussed by an MDT prior to treatment; this discus-
sion should be documented in MDT outcomes.
Where treatment needs to be expedited (prior to or follow-
ing MDT discussion) there should be an agreed pathway so as to 
not delay treatment. MDT discussion should still occur and be 
recorded.
4.6.2 | Treatment planning pathway
The agreed treatment pathway should ideally be formulated at the 
first MDT for ALL patients.
That agreement must either prescribe definitive treatment OR 
outline necessary investigations leading to final treatment plan.
The aim of treatment (curative/palliative) should be documented in 
MDT outcomes for ALL individuals being discussed within that MDT.
In ALL cases, the recommended treatment plan should be com-
municated to the individual and carers verbally, to the GP in writing.
5  | INPATIENT C ARE
5.1 | Nursing staff
The nurse in charge on each shift should have a specialist qualifica-
tion in a related discipline and a minimum of 5 years of experience.
Two other nurses on the staff should have, or be preparing for, a 
specialist qualification in related disciplines.
Nursing staff (including health care assistants) should have com-
petencies associated with altered airway management and major 
haemorrhage in the head and neck setting.
Nurses should be informed and aware of ongoing clinical re-
search projects, audits and clinical trials.
5.2 | Head and neck care
Higher advice at experienced specialist registrar AND consultant 
level to be available 24 hours a day, every day.
5.3 | Other staffing
Named speech and language therapist, dietitian/nutritional nurse 
specialist, physiotherapist, pharmacist, dental hygienist, psycholo-
gist and social worker.
ALL individuals should:
• Have access to dedicated inpatient dietetic, physiotherapy, occu-
pational therapy and speech and language/swallowing therapy, 
clinical nurse specialist. Further detail of their broader roles is 
provided below. This applies equally to people recovering from 
surgery and to those admitted with treatment- related toxicities.
Multidisciplinary assessment in line with pre- habilitation and en-
hanced recovery protocols is to be encouraged in ALL units and for 
ALL individuals.
5.4 | Patient admission
Patients should be provided with proposed treatment dates within 
national targets/guidelines in ALL cases.
Arrangements should be available for pre- operative assessment 
prior to admission in ALL units delivering surgical treatment for head 
and neck cancer.
Comprehensive multidisciplinary discharge planning should be 
instigated at admission. This might include feeding arrangements, 
airway/tracheostomy care and mouth care.
5.5 | Operating theatres
5.5.1 | Staffing
The senior nurse should have a specialist qualification in a related 
discipline.
Staff should include one other nurse with or studying specialist 
qualification in a related discipline.
Theatre staff should have an adequate skill set to manage the full 
range of head and neck cancer patients. Specialist ongoing training 
in head and neck procedures should be available for all members of 
the theatre staff.
5.5.2 | Anaesthetics
There should be one or more named consultant anaesthetist(s) with 
advanced expertise in head and neck anaesthesia and complex air-
way management (inc. jet ventilation, awake fibre- optic intubation). 
They should be responsible for directly or indirectly overseeing 
100% of major head and neck operations.
5.5.3 | Provision of equipment in centres offering 
diagnostic procedures
• Capability to record photographic/digital imaging
• Appropriate endoscopy and biopsy facilities with associated 
instrumentation.
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5.5.4 | Provision of equipment in centres offering 
treatment surgery procedures
This should include:
• A range of Hopkins rod telescopes.
• Laser instrumentation (suitable for head and neck use).
• Two- headed operating microscope appropriate for microvascular 
surgery and associated microvascular instruments.
This is not an exhaustive list, and other available equipment 
should include all materials, technologies and resources befitting of 
a service delivering high- quality care.
5.5.5 | Provision of facilities
Adequate theatre capacity for extended day theatre session for 
major/complex procedures (eg three- session lists if needed).
ALL units must retain availability of HDU and ITU in the same 
building.




ALL individuals with early laryngeal cancer should have a pathway to 
discuss transoral laser surgery as well as radiotherapy.
Units treating individuals with advanced disease should provide 
ALL individuals with access to resective and reconstructive surgical 
options, and appropriate adjuvant treatments.
6.1.2 | Oral
ALL units should offer or have a pathway to offer sentinel node bi-
opsy for ALL individuals with early oral SCC
6.1.3 | Oropharynx
ALL units should have a pathway for offering minimally invasive sur-
gical alternatives— transoral robotic surgery (TORS) and/or transoral 
laser microsurgery (TLM).
6.1.4 | Hypopharynx
ALL individuals with early hypopharyngeal cancer should have a 
pathway to discuss organ- preservation treatment.
Units treating individuals with advanced disease should provide 
ALL individuals with access to resective and reconstructive surgical 
options, and appropriate adjuvant treatments.
6.1.5 | Cancer of unknown primary
ALL units treating individuals with unknown primary tumours of the 
head and neck should have access to 18- fluorodeoxyglucose posi-
tron emission tomography (FDG PET)- CT scanning facilities.
Excisional biopsy of the malignant (suspected or otherwise) neck 
mass must not be undertaken without prior discussion in the special-
ist head and neck MDT.
There should be an agreed protocol for the surgical assessment 
of the primary site when FDG PET- CT does not identify a possible 
primary site. There should be an agreed pathway for a tongue base 
mucosectomy where indicated.
6.1.6 | Salivary gland malignancy
ALL primary salivary gland malignancies must be discussed in the 
head and neck MDT.
These rare tumours require specialist care including access 
to appropriate histopathological expertise and diagnostic mo-
lecular testing (or a pathway to provide tertiary opinion where not 
available).
All units treating parotid malignancies should have a pathway for 
rehabilitation of facial nerve function.
6.1.7 | Skull base malignancy
All malignant skull base tumours should be discussed within a spe-
cialist skull base MDT, to include:
• Head and neck ablative surgeon with appropriate expertise in 
skull base surgery (anterior and lateral skull base with sufficient 
numbers of cases)
• Neurosurgeon
• Reconstructive surgeon (see below)
• Head and neck oncologist.
6.2 | Reconstruction
6.2.1 | Provision of techniques
Surgeons providing reconstruction for head and neck defects must 
have a specialist interest in head and neck surgery with prior training 
and experience.
The range of reconstructive options offered by reconstructive 
surgeons must be commensurate with the ablative defect and be 
deemed to be contemporary practice.
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Where this is not available, units must be able to offer onward 
referral, or have documented referral pathways to specialist centres 
providing such services, ensuring ALL reconstructive options are 
available for ALL individuals.
ALL units providing this reconstructive service must have sys-
tems in place to achieve a timely AND safe return to theatre where 
necessary, ensuring the appropriate surgical skill mix is available at 
all times. Provision of a reconstructive service must be supported by 
a robust microvascular on- call service.
The minimum indicative number of free flap cases un-
dertaken within an individual MDT structure should exceed 25 per 
annum.
Free flap success for ALL units must exceed 90% and ideally be 
above 95%.
ALL surgeons providing head and neck reconstructive services 
should maintain documented evidence of the number of flaps un-
dertaken annually with associated success rates, so as to facilitate 
comparison within their unit/MDT structure.
ALL units should audit free flap outcomes annually including:
• Number of free flap procedures undertaken
• Returns to theatre
• Salvage rates
• Overall success (partial or otherwise)
• Patient length of stay.
ALL units should be prepared to present their outcomes follow-
ing free flap reconstruction for external peer review.
6.3 | Radiotherapy
6.3.1 | Quality
IMRT in ALL cases where critical sparing would not be achievable by 
3D conformal radiotherapy planning.
Peer review ALL curative H&N radiotherapy contours before 
treatment begins.
There should be a minimum of two head and neck clinical on-
cologists in each unit to provide seamless continuity of service and 
optimise quality.
6.3.2 | Timing
ALL radical treatments should start within 17 days of the decision 
to treat with recording of clinically justifiable delays. This path-
way should be audited regularly to enable redesign to facilitate 
improvement.
For radiotherapy delivered with palliative intent, treatment 
should commence within 14 days of the decision to treat.
All unplanned breaks must be managed according to RCR criteria.
Completion of adjuvant therapy should aim to be within 100 
days of commencement of definitive therapy in ALL cases. Extension 
of this time frame should only be where patient- specific factors dic-
tate this need.
6.3.3 | Regimens
ALL centres to have written protocols for different tumour sites and 
intents, either produced locally or using national guidelines. These 
should be reviewed and updated in the light of research trial evi-
dence at least every two years.
6.4 | Systemic anticancer therapy
6.4.1 | Chemotherapy, monoclonal antibodies and 
immunotherapy regimens
Evidence- based guidelines for the use of chemoradiotherapy and for 
palliative systemic therapies should be present in 100% of units.
6.4.2 | Compliance
Any deviation from national protocols needs to be documented and 
agreed within MDT structures.
6.5 | Allied health professionals
6.5.1 | Holistic needs assessment
All patients should be offered a holistic needs assessment at diagno-
sis, post- treatment and as required thereafter— this allows healthcare 
professionals to understand needs and signpost to other services as 
appropriate.
Discharge planning, feeding/airway/community support, etc., 
should begin prior to admission.
6.5.2 | Clinical Nurse Specialist (CNS)
ALL units should make adequate provision of CNS posts/individuals 
to ensure the following essential care elements can be provided at 
all times:
• CNS involvement in ALL MDT meetings
• Psychosocial support and care co- ordination for ALL individuals 
being managed in the unit (at varying extent)
• CNS contact with all individuals at the time of diagnosis
• Availability to provide co- ordination of multiprotection care pathways
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• Accessibility as a point of contact for expert advice to primary 
care physicians, district nurses, palliative care teams, etc. (eg tra-
cheostomy and gastrostomy care and wound care)
• Co- ordinated, tailored approach to the provision of support for 
individuals living with the effects of cancer and long- term con-
sequences of cancer treatment. This should include end of treat-
ment summaries, health and well- being advice, signposting to 
resources available and appropriate follow- up.
6.5.3 | Speech and language therapist/pathologist
ALL units should have a named speech and language/ swallowing 
therapist with at least 50% of time dedicated to head and neck can-
cer care and with specialist surgical voice restoration skills.
ALL individuals who are undergoing treatment likely to disrupt 
communication or swallowing function should be seen by a speech 
and language therapist for pre- treatment counselling and a baseline, 
multidimensional assessment of speech, voice and swallowing, in-
cluding clinician and patient- reported outcome measures.
The following should be available in ALL units:
• Access to videofluoroscopy and fibre- optic endoscopic evalua-
tion of swallowing (FEES)
• A speech and swallowing therapist present at ALL examinations. 
The assessment of the nature/extent of any oropharyngeal dys-
phagia should support and inform compensatory strategies and 
therapeutic intervention.
• Multidisciplinary assessment in line with pre- habilitation and en-
hanced recovery protocols
• Access for ALL individuals to speech, voice and swallowing ther-
apy as required, for example on- treatment radiotherapy clinics, in 
the post- operative setting and at outpatient facilities.
6.5.4 | Dietitian
ALL units should have a named dietitian with at least 50% of time 
dedicated to head and neck cancer work with specialist knowledge 
in tube feeding and altered textured diets.
ALL Individuals should be nutritionally screened using a vali-
dated tool. Those who are malnourished, or at risk of malnutrition, 
should be referred to the dietitian for early intervention and nutri-
tion support.
ALL individuals who are undergoing treatment likely to signifi-
cantly impact on their ability to meet their nutritional requirements 
should be seen by a specialist dietitian for pre- treatment counselling.
The following should be available in ALL units:
• A baseline assessment should be conducted to assess nutritional 
status and discuss the need for nutritional support prior, during or 
after treatment including NG or gastrostomy (PEG or RIG) and/or 
including prophylactic placement
• As appropriate, the findings of baseline assessments should be 
made available for discussion at the head and neck MDT to inform 
treatment planning
• Access for ALL individuals to a dietitian as required, for example 
on- treatment radiotherapy clinics, in the post- operative setting 
and at outpatient facilities
If patients are to be referred on to local services, dietitians and 
speech and language therapists should be available in a consultancy 
role to support providers in primary care.
6.5.5 | Dental/prosthodontic care and rehabilitation
ALL units should have a named Consultant in Restorative Dentistry 
to lead the dental and oral rehabilitation of patients. A Consultant 
in Restorative Dentistry should lead pre- treatment oral and dental 
assessment and planning.
ALL patients undergoing ablative treatment that will alter oral 
and dental function (including risk of osteoradionecrosis) and/
or appearance should also be assessed for dental extractions 
prior to treatment. Pathways for dental treatment/extractions 
should be configured so as to avoid delays to definitive cancer 
treatment.
A suitably qualified practitioner should be available to pre- 
operatively assess ALL patients who may require orbital, nasal and 
auricular prostheses. ALL Units should provide (or have a pathway to 
facilitate) implant- retained prostheses.
ALL individuals should be assessed before and after their main 
treatment, and this should be led by a Consultant in Restorative 
Dentistry.
ALL individuals should have access to a suitably experienced 
dental therapist or hygienist.
ALL dentate individuals should have high concentration of fluo-
ride toothpaste prescribed.
The pre- treatment planning for ALL patients requiring extensive 
resections involving the tooth- baring tissues should involve a suit-
ably trained restorative dentist.
6.5.6 | Physiotherapy
All centres should have pathways for physiotherapy following 
surgery.
Progressive resistance training for people with impaired shoulder 
function should be considered as soon as possible after neck dissection.
6.5.7 | Psychological care
Individuals receiving head and neck cancer care should have access 
to psychology services, in particular a psychologist with a defined 
head and neck interest (occupying 25% of job plan).
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ALL permanent medical, nursing and allied health professional 
staff should be aware of written protocols and referral routes for 
psychological support.
6.5.8 | Addiction support and counselling
Smokers should be offered help to stop smoking in line with the 
NICE guideline on stop smoking interventions and services. ALL 
individuals and carers should be informed at the point of diagnosis 
that continuing to smoke will adversely affect outcomes including 
treatment- related side effects, risk of recurrence and the risk of sec-
ond primary cancers.
All patients with alcohol dependency and/or drug misuse should 
be offered local support before treatment. Heavy- use alcohol and 
drug dependents may need to be hospitalised for several days pre- 
surgery to enable safe detox and withdrawal monitoring.
6.5.9 | Palliative care medicine
Hospital medical and nursing staffing
ALL centres to have written guidelines agreed with the local pallia-
tive care consultant(s).
ALL units should provide staff training and necessary equipment 
to support endoluminal debulking of tumours to avoid tracheostomy.
Agreed pathways should exist for tracheostomy advanced care 
decision- making.
Amongst ALL permanent staff there should be:
• Awareness of protocols for cancer pain management
• Awareness of neuropathic pain and routine management 
strategies
• Knowledge of route of referral to palliative care (person, place, 
method).
Crisis planning
ALL units and hospices managing individuals with head and neck 
cancer should adhere to local guidelines for tracheostomy blockage 
and major haemorrhage.
ALL specialist head and neck ward nurses should be aware of 
these protocols.
Individuals (and their carers) at risk of these crises should be 
made aware of the warning signs in ALL cases unless the patient has 
expressed a wish to not be provided with this information.
Living with cancer
An individual approach to end of life care (last 12 months of life), in-
cluding clear documentation and communication with each relevant 
team providing palliative care, must be employed for ALL individu-
als. This may include liaison with primary care and specialist pallia-
tive care teams. Clear offers must be made to discuss and implement 
advance care plans with all patients. These may reasonably include 
patients’ preferred place of care, agreed thresholds or ceilings of 
treatment.
For those recognised to be dying (last days of life), an individual-
ised care plan should support care for ALL individuals.
7  | THYROID C ANCER
The clinical management of thyroid cancer is not intended to be 
addressed in detail within this document. Detailed guidelines on 
management of thyroid cancer are already contained within a com-
prehensive publication produced by the British Thyroid Association 
(BTA). BAHNO intends this section on thyroid cancer to be com-
plementary to these and supplementary to the standards already 
described for the management of upper aerodigestive tract (UAT) 
cancer.
The management of differentiated thyroid cancer (DTC) (a highly 
curable disease) and of medullary thyroid cancer (MTC) should be 
the responsibility of a specialist MDT. The membership of this will 
normally be appointed by the regional cancer network.
In this section, we highlight guiding principles of management of 
thyroid cancer. Many of the principles take origin from the Improving 
Outcomes in Head and Neck Cancers, 2004, and the Manual for 
Cancer Services 2008, Head and Neck Measures.
NICE guidance is expected to be released in April 2022.
7.1 | Principles
ALL patients with thyroid cancer, including those whose cancer is 
discovered after surgery for apparently benign disease, should be 
referred for discussion of the patient’s management by a thyroid 
cancer MDT.
The management of thyroid cancer should be the responsibility 
of the specialist MDT, membership of which will normally be agreed 
by the regional cancer network and according to the Manual for 
Head and Neck Cancer services.
Patient- shared decisions are important for a significant number 
of patients, particularly in areas with no clear evidence base to di-
rect management. This could apply equally to those with low- risk or 
advanced- stage disease. This may be based on patient views, con-
cerns and willingness to undergo long- term follow- up.
Where possible, patients should be considered for enrolment in 
clinical trials.
MDTs for thyroid cancer may function separately from those 
managing UAT, or as part of a combined MDT with a UAT team and 
they should cover a minimum catchment population of one million 
for referral of thyroid cancer.
ALL members of the designated MDT should have a specialist 
interest in the management of thyroid cancers and should include:
• Thyroid surgeon
• Pathologist




• Nuclear medicine physician
• Medical physicist
• Clinical nurse specialist.
All members of the MDT should maintain thyroid- specific con-
tinuing professional development.
Patients will normally be seen by one or more members of the 
MDT; a combined clinic is recommended.
7.2 | Diagnosis
In many cases, investigation of a neck lump will have a common path-
way both in UAT metastasis and in thyroid cancer.
The use of BTA U1- U5 or TIRADS1- 5 ultrasound scoring/grading 
systems is recommended for assessing risk of malignancy and guid-
ing the need for fine- needle aspiration cytology.
As with UAT cancers, fine- needle aspiration biopsy should be 
carried out by a suitably trained specialist, ideally with ultrasound 
guidance. This should be offered within a designated neck lump 
pathway— if possible as a “one- stop” process.
Thyroid cytology should be reported by a cytopathologist with 
experience in thyroid disease and with access to colleagues with ad-
ditional experience for second opinions when appropriate. The cy-
tology report should contain a descriptive section interpreting the 
findings, followed by the “Thy” numerical category as defined by the 
Royal College of Pathologists.
7.3 | Treatment
In the UK, thyroid surgery is carried out by many specialties (ear 
nose and throat surgery, endocrine surgery, oral and maxillofacial 
surgery, general surgery). ALL surgeons must have training and ex-
pertise in the management of thyroid cancer and be a core member 
of the multidisciplinary team (MDT) managing thyroid cancer.
It is expected that ALL surgeons involved in the care of pa-
tients with thyroid cancer submit their data to an approved audit, 
for example that of British Association of Endocrine and Thyroid 
Surgeons.
Surgeons should perform a minimum of 20 thyroid operations 
per year.
Surgery for locally advanced thyroid cancer requiring lateral 
neck dissection should be centralised within each MDT network 
under the care of recognised surgeons. Similar arrangements should 
be agreed within the MDT network for the care of patients with 
medullary thyroid cancer.
Histopathologists reporting thyroid tumours should have a spe-
cial interest in thyroid pathology or participate in a network with 
the opportunity of pathology review. Reporting of specimens should 
include the nationally agreed minimum data sets as per RCPath 
guidelines.
A clinical oncologist or nuclear medicine physician treating thy-
roid cancer should have training and expertise in the management of 
thyroid cancer and be a core member of the MDT managing thyroid 
cancer.
Information on ALL patients diagnosed and treated for thyroid 
cancer should be collected using approved local cancer network or 
national databases. Outcomes should be subject to regular audit.
8  | RESE ARCH AND AUDIT
8.1 | Clinical trials
There should be a named clinical lead and nurse practitioner for 
head and neck research.
ALL head and neck clinicians (including trainees) should be en-
couraged to gain Good Clinical Practice (GCP) Certification (the 
international ethical, scientific and practical standard to which all 
clinical research is conducted).
ALL MDTs should be aware of the current head and neck studies 
in the NCRI national portfolio pf clinical studies.
Where a trial or research study exists, individuals should be pro-
vided with an opportunity to be included (or onward referral to a 
unit that can offer recruitment in the situation where an individual 
chooses).
There should be published statistics of recruitment to clinical 
studies.
8.2 | Governance and clinical audit
ALL clinicians should be involved in the process and outcome of clini-
cal audit.
The results of audit (local and national) should be publicly avail-
able and where appropriate, published in peer- reviewed journals for 
wider dissemination and uptake.
ALL units should, as a minimum, undertake an annual audit of 
clinical outcomes and a review of governance structures.
This audit should include the following key performance 
indicators:
• New cases of head and neck squamous cell carcinoma
a. Each unit should audit the number of new patients with head 
and neck cancer (excluding haematological cancers) annu-
ally and record the number of head and neck cancer opera-
tions (including the number of neck dissections and free flap 
procedures).
• Pathological assessment of margins
a. this document has removed the historical numerical standard 
measuring the achievement of clear surgical margins. This reflects 
a move towards more conservative surgical techniques. However, 
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adequate surgical excision remains paramount, especially for indi-
viduals undergoing single modality surgical treatment. Individual 
MDTs should demonstrate a clear process of governance regard-
ing surgical margins and oncological outcomes.
• Surgery— as above for reconstruction; free flap success rate
• Oncology
a. Proportion of patients requiring primary radical (chemo)radio-
therapy starting within 17 days start from the date of decision 
to treat
b. proportion of patients completing adjuvant treatment within 
100 days of surgery
c. proportion of patients who receive radical radiotherapy hav-
ing peer review of treatment volumes
d. proportion of patients requiring replanning during a radical 
course of radiotherapy
• Speech and Language Therapy
a. ALL individuals undergoing treatment likely to disrupt com-
munication or swallowing function to be seen by special-
ist Head and Neck cancer speech and language therapist 
pre- treatment
b. Minimum of one clinician- assessed and one patient- reported 
outcome measure pre- treatment, post- treatment and at 
discharge
c. Recommended measures as follows:
▪ Clinician assessed: PSS- HN, 100 mL water swallow test, 
GRBAS, MIO
▪ Patient- reported: MDADI, Speech Handicap Index (as ap-
propriate), VHI
▪ The PSS- HN, 100 mL WST, GRBAS, MIO, MDADI are consid-
ered the optimal minimum dataset at baseline, 3 and 12 months
d. ALL individuals to be seen by SLT during radiotherapy (>60 Gy)
e. Instrumental swallowing evaluation (FEES/VF) in ALL people 
undergoing surgery following chemoradiation, reirradiation 
and/ or targeted therapies as appropriate for residual/ re-
current disease (instrumental reporting to include validated 
measures— PAS, DIGEST, NZ Secretion Scale, Yale Residue 
Scale, Patterson Oedema Scale as appropriate).
• Dietetics
a. Feeding within 24 hours of surgery as part of an enhanced re-
covery after surgery (ERAS) protocol
b. Aim for maintenance of weight (<10% weight loss) during the 
period between initial consultation/diagnosis and 6 months 
post- completion of treatment.
c. ALL individuals to be seen by specialist head and neck dietitian 
at least once a week during radiotherapy treatment (>60gy) 
and as required for rehabilitation
d. ALL individuals to be seen by specialist head and neck dietitian 
pre- treatment.
• Head and neck nursing and holistic care
a. ALL patients should see a CNS at the time of diagnosis.
b. ALL patients should be offered an holistic needs assessment 
at diagnosis, following treatment and at any other significant 
time during their cancer journey.
c. ALL patients should have access to psychological support.
• Restorative dentistry
a. ALL patients should receive a dental assessment (including 
DPT) prior to and after any treatment that impacts upon the 
oral cavity.
b. ALL dentate patients shall be prescribed high concentration 
fluoride unless otherwise contraindicated.
c. ALL patients should receive oral hygiene instruction by a suit-
ably trained member of the dental team.
• Palliative care
a. ALL expected inpatient deaths should be reviewed as to 
whether care in the last days of life was supported with an 
individualised care plan.
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